Luni Emdad1, Aleksandar Janjic1, Mohammad A Alzubi1, Bin Hu1, Prasanna K Santhekadur1, Mitchell E Menezes1, Xue-Ning Shen1, Swadesh K Das1, Devanand Sarkar1, Paul B Fisher1. 1. Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia (L.E., A.J., M.A.-Z., B.H., P.K.S., M.E.M., X.-N.S., S.K.D., D.S., P.B.F.); VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia (L.E., S.K.D., D.S., P.B.F.); VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia (L.E., D.S., P.B.F.).
Abstract
BACKGROUND: Malignant glioma is an aggressive cancer requiring new therapeutic targets. MicroRNAs (miRNAs) regulate gene expression post transcriptionally and are implicated in cancer development and progression. Deregulated expressions of several miRNAs, specifically hsa-miR-184, correlate with glioma development. METHODS: Bioinformatic approaches were used to identify potential miR-184-regulated target genes involved in malignant glioma progression. This strategy identified a multifunctional nuclease, SND1, known to be overexpressed in multiple cancers, including breast, colon, and hepatocellular carcinoma, as a putative direct miR-184 target gene. SND1 levels were evaluated in patient tumor samples and human-derived cell lines. We analyzed invasion and signaling in vitro through SND1 gain-of-function and loss-of-function. An orthotopic xenograft model with primary glioma cells demonstrated a role of miR-184/SND1 in glioma pathogenesis in vivo. RESULTS: SND1 is highly expressed in human glioma tissue and inversely correlated with miR-184 expression. Transfection of glioma cells with a miR-184 mimic inhibited invasion, suppressed colony formation, and reduced anchorage-independent growth in soft agar. Similar phenotypes were evident when SND1 was knocked down with siRNA. Additionally, knockdown (KD) of SND1 induced senescence and improved the chemoresistant properties of malignant glioma cells. In an orthotopic xenograft model, KD of SND1 or transfection with a miR-184 mimic induced a less invasive tumor phenotype and significantly improved survival of tumor bearing mice. CONCLUSIONS: Our study is the first to show a novel regulatory role of SND1, a direct target of miR-184, in glioma progression, suggesting that the miR-184/SND1 axis may be a useful diagnostic and therapeutic tool for malignant glioma.
BACKGROUND:Malignant glioma is an aggressive cancer requiring new therapeutic targets. MicroRNAs (miRNAs) regulate gene expression post transcriptionally and are implicated in cancer development and progression. Deregulated expressions of several miRNAs, specifically hsa-miR-184, correlate with glioma development. METHODS: Bioinformatic approaches were used to identify potential miR-184-regulated target genes involved in malignant glioma progression. This strategy identified a multifunctional nuclease, SND1, known to be overexpressed in multiple cancers, including breast, colon, and hepatocellular carcinoma, as a putative direct miR-184 target gene. SND1 levels were evaluated in patienttumor samples and human-derived cell lines. We analyzed invasion and signaling in vitro through SND1 gain-of-function and loss-of-function. An orthotopic xenograft model with primary glioma cells demonstrated a role of miR-184/SND1 in glioma pathogenesis in vivo. RESULTS:SND1 is highly expressed in humanglioma tissue and inversely correlated with miR-184 expression. Transfection of glioma cells with a miR-184 mimic inhibited invasion, suppressed colony formation, and reduced anchorage-independent growth in soft agar. Similar phenotypes were evident when SND1 was knocked down with siRNA. Additionally, knockdown (KD) of SND1 induced senescence and improved the chemoresistant properties of malignant glioma cells. In an orthotopic xenograft model, KD of SND1 or transfection with a miR-184 mimic induced a less invasive tumor phenotype and significantly improved survival of tumor bearing mice. CONCLUSIONS: Our study is the first to show a novel regulatory role of SND1, a direct target of miR-184, in glioma progression, suggesting that the miR-184/SND1 axis may be a useful diagnostic and therapeutic tool for malignant glioma.
Authors: Jie Yang; Saara Aittomäki; Marko Pesu; Kara Carter; Jussi Saarinen; Nisse Kalkkinen; Elliott Kieff; Olli Silvennoinen Journal: EMBO J Date: 2002-09-16 Impact factor: 11.598
Authors: Amy A Caudy; René F Ketting; Scott M Hammond; Ahmet M Denli; Anja M P Bathoorn; Bastiaan B J Tops; Jose M Silva; Mike M Myers; Gregory J Hannon; Ronald H A Plasterk Journal: Nature Date: 2003-09-25 Impact factor: 49.962
Authors: Nan Wang; Xilin Du; Li Zang; Nuan Song; Tao Yang; Rui Dong; Tao Wu; Xianli He; Jianguo Lu Journal: Mol Biol Rep Date: 2012-10-14 Impact factor: 2.316
Authors: Timothy P Kegelman; Swadesh K Das; Bin Hu; Manny D Bacolod; Christine E Fuller; Mitchell E Menezes; Luni Emdad; Santanu Dasgupta; Albert S Baldwin; Jeffrey N Bruce; Paul Dent; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher Journal: Neuro Oncol Date: 2013-12-04 Impact factor: 12.300
Authors: M Cappellari; P Bielli; M P Paronetto; F Ciccosanti; G M Fimia; J Saarikettu; O Silvennoinen; C Sette Journal: Oncogene Date: 2013-09-02 Impact factor: 9.867
Authors: Heidi G Møller; Andreas P Rasmussen; Hjalte H Andersen; Kasper B Johnsen; Michael Henriksen; Meg Duroux Journal: Mol Neurobiol Date: 2012-10-02 Impact factor: 5.590
Authors: Nidhi Jariwala; Devaraja Rajasekaran; Rachel G Mendoza; Xue-Ning Shen; Ayesha Siddiq; Maaged A Akiel; Chadia L Robertson; Mark A Subler; Jolene J Windle; Paul B Fisher; Arun J Sanyal; Devanand Sarkar Journal: Cancer Res Date: 2017-04-20 Impact factor: 12.701